Optimising Treatments for Faecal Incontinence

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-12-15

Study Completion Date

2018-09-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to directly compare two medical treatments for faecal incontinence: Renew™ Anal Insert and Percutaneous Tibial Nerve Stimulation (PTNS) for a period of 12 weeks. Both are routinely used in our practice.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Long-term Efficacy of Percutaneous Tibial Nerve Stimulation Applied to Patients With Faecal Incontinence.

NCT05016453

Faecal Incontinence

COMPLETED

Tibial Nerve Stimulation for Faecal Incontinence

NCT00530933

Fecal Incontinence

UNKNOWN NA

UK Trial of Percutaneous Tibial Nerve Stimulation in Patients With Faecal Incontinence

NCT02349334

Faecal Incontinence Bowel Incontinence

COMPLETED PHASE3

Does Percutaneous Tibial Nerve Stimulation (PTNS) Improve Outcomes in Patients Presenting With Fecal Incontinence

NCT01274585

Fecal Incontinence

TERMINATED NA

A Study to Evaluate the Safety, Tolerability and Effectiveness of the Renew Insert in Treating Accidental Bowel Leakage

NCT01475474

Bowel Incontinence

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The Renew™ anal insert is a new single-use anal device, CE marked and widely used in the UK and Europe. It is indicated for the management of faecal incontinence and designed to seal and prevent the involuntary passage of stool from the rectum. The device is intended for self-insertion aided by a fingertip applicator.

Percutaneous tibial nerve stimulation (PTNS) is a form of electrical stimulation that offers a simple minimally invasive outpatient treatment for faecal incontinence. A fine needle is inserted next to the tibial nerve above the ankle, a ground pad is attached to the heel and electric current just strong enough to cause minor tingling is passed between these two points. The treatment requires 12 outpatients sessions that are 30 minutes long each time and the treatment may be repeated.

Patients will be randomly allocated to either receive PTNS therapy or the Renew™ device. This will be done by the investigators randomly selecting a sealed envelope that is not see-through from a large number of identical envelopes. Each of these envelopes will contain either the word PTNS or the word Renew, which will then determine patients' treatment. There will be an equal number of PTNS and Renew envelopes to make this decision truly random. The principal investigator of this study will not know which treatment patients have been allocated to until after the study is complete. Patients who wish to change treatment before the study ends will be withdrawn from the study.

During the study the investigators will ask patients to complete some standard questionnaires that are normally used to score the degree of the incontinence and to assess bowel symptoms.: These will be completed at the hospital during the standard clinic consultation, both before patients start the treatment and after having completed the treatment course.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Faecal Incontinence Pelvic Floor Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Patients who have completed the treatment can switch to the other treatment offered.

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Both participants and first investigator will be masked from the actual treatment.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Renew Anal Insert

The device is intended for self-insertion through the anal canal aided by a fingertip applicator.

Group Type ACTIVE_COMPARATOR

Renew VS PTNS

Intervention Type DEVICE

These will be prescribed and applied as described above.

Percutaneous tibial nerve stimulation

A fine needle is inserted next to the tibial nerve above the ankle, a ground pad is attached to the heel and electric current just strong enough to cause minor tingling is passed between these two points.

Group Type ACTIVE_COMPARATOR

Renew VS PTNS

Intervention Type DEVICE

These will be prescribed and applied as described above.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Renew VS PTNS

These will be prescribed and applied as described above.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Passive or mixed faecal incontinence.
* Minimum two or more episodes of faecal incontinence per week as assessed by prospectively collected bowel diaries.
* Failed biofeedback, pelvic floor physiotherapy or other medical management.
* Able to self- administer the Renew™ Anal Insert.
* Competent and willing to fill in questionnaires and attend clinics throughout the study.
* Patient must be able to comprehend and informed consent prior to enrolment in the study.

Exclusion Criteria

* Pregnancy.
* Inability to given informed consent.
* Perianal sepsis.
* Rectal bleeding.
* Inflammatory bowel disease/ Proctitis.
* Rectal prolapse.
* Third or fourth-degree hemorrhoids.
* Anal stricture.
* Anal or Recto-vaginal fistula.
* Rectal surgery in the past 3 months.
* Known allergy to Silicone.
* Patients who are mentally or physically unable to comply with the protocol of the study.
* The presence of any other medical condition which, in the opinion of the Chief Investigator, deems the patient unsuitable for participation in the study.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes